XERS Xeris Biopharma Inc Company Total Asset Base

Official company branding of Xeris Biopharma Holdings, Inc. (XERS)

This chart reflecting the value dynamics of Xeris Biopharma (XERS) total assets on the GURU.Markets platform recorded a figure of 373.04. The business is shielded from sanctions and trade conflicts due to the localization of its production facilities. Xeris Biopharma (XERS) is developing unique XeriSol and XeriLect systems, simplifying drug administration for diabetes. Meanwhile, strict adherence to temperature controls during transport ensures the flawless quality of the finished injections.

Xeris Biopharma Inc - XERS Company Total Assets (period 07/04/2022 - 10/31/2026)

Financial and market metric breakdowns for Xeris Biopharma Inc (XERS)

- current quotes and average value forecast:
Market Chart xerispharma.com|XERS - Price Target Chart
- market capitalization data:
Market Capitalization Xeris Pharma|XERS - Total Company Value
- shareholders' equity book value data:
Share Book Value Xeris Biopharma|XERS - Book Capitalization|Market-to-Book Ratio xerispharma.com|XERS - Company Total Assets
- debt and liquidity details:
Total Debt to Equity Ratio Xeris Biopharma|XERS - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Xeris Pharma|XERS - Company Aggregate Debts|Debts to Book Capitalization Xeris Pharma|XERS - Company Long-Term Debt|Company Short-Term Debt Xeris Biopharma|Interim Coverage Ratio xerispharma.com
- financial results and valuation multiples details:
XERS - Net Income
Fundamental valuation:Xeris Biopharma
Core merchandise of Xeris Biopharma

The commercialization of the Xeris Biopharma (XERS) drug portfolio is activating operating leverage, enabling margin scaling through the reduction of unit costs. The trend in total assets, reverse-calculated via ROA, reflects the efficiency of capital and debt utilization for profit generation, serving as an indicator of business resilience and providing investor protection against portfolio impairment risks during credit shocks.

Main competitors

VRTX - Company Total Asset Base|Aggregate Company Assets Alnylam|Insmed Inc. (INSM) - Company Total Asset Base|Aggregate Company Assets United Therapeutics Corp. (UTHR)|BMRN: Total Asset Value of Company|Company Total Assets BBIO (BridgeBio Pharma, Inc.)|BGM Group Limited (BGM) - Company Assets|Cogent Biosciences, Inc. - Company Total Assets|Keros Therapeutics Inc (KROS) - Cumulative Company Assets|ARCT: Company Total Assets|ETON - Company Total Asset Base|KMDA (Kamada Ltd.) - Company Total Assets|Company Total Assets fulcrumtx.com|Aggregate Company Assets Abeona Therapeutics (ABEO)|Aggregate Company Assets MREO (mereobiopharma.com)|Company Total Assets PLX (Protalix)|Company Total Asset Base Pliant Therapeutics Inc (PLRX)|APLT: Cumulative Company Assets|Total Asset Value of Company RNTX|GELS: Company Total Assets|Company Assets Aytu BioPharma (AYTU)|CMMB (Chemomab Therapeutics Ltd) - Company Total Assets|Total Business Assets SRXH (SRx Health)|Cumulative Company Assets PLRZ (Polyrizon Ltd)|AEZS (zentaris.com) - Aggregate Asset Value|Aggregate Company Assets Cyclo Therapeutics, Inc. CYTH|INZY (Inozyme Pharma Inc.) - Total Asset Value of Company|Reneo Pharma - Company Total Assets|Aggregate Asset Value CSCI (COSCIENS Bio)